SPARQL
Query
Update
Search
Quick
Advanced
Co-occurrence
RelFinder
About
Sources
Admin
System Info
Repository Management
Search Configuration
Sources
11299740
Source:
http://linkedlifedata.com/resource/pubmed/id/11299740
Search
Subject
(
61
)
Predicate
Object
All
Download in:
JSON
RDF
N3/Turtle
N-Triples
Switch to
Custom View
Named Graph
All
UniProt
NCBIGene
DrugBank
ClinicalTrials
UMLS
PubMed
Mappings
MentionedEntities
Language
All
English
Español
Português
Français
Deutsch
Русский
日本語
Български
Inference
Explicit and implicit
Explicit only
Implicit only
Statements in which the resource exists as a subject.
Predicate
Object
rdf:type
pubmed:Citation
lifeskim:mentions
umls-concept:C0006826
,
umls-concept:C0007634
,
umls-concept:C0079419
,
umls-concept:C0729502
,
umls-concept:C1155874
pubmed:issue
1A
pubmed:dateCreated
2001-4-12
pubmed:abstractText
Chkl is a checkpoint gene that is activated after DNA damage. It phosphorylates and inactivates Cdc25C at the late G2 phase. The inactivation of Cdc25C and consequently, the inactivation of Cdc2, are required for the G2 arrest induced by DNA damage.
pubmed:language
eng
pubmed:journal
http://linkedlifedata.com/resource/pubmed/journal/8102988
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/7-hydroxystaurosporine
,
http://linkedlifedata.com/resource/pubmed/chemical/Alkaloids
,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents
,
http://linkedlifedata.com/resource/pubmed/chemical/Checkpoint kinase 1
,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin
,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors
,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinases
,
http://linkedlifedata.com/resource/pubmed/chemical/Staurosporine
,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53
pubmed:status
MEDLINE
pubmed:issn
0250-7005
pubmed:author
pubmed-author:BradneyMM
,
pubmed-author:ButlerC CCC
,
pubmed-author:GirandaV LVL
,
pubmed-author:GubbinsE JEJ
,
pubmed-author:HolzmanT FTF
,
pubmed-author:JosephM KMK
,
pubmed-author:LuoYY
,
pubmed-author:NgS CSC
,
pubmed-author:PaiM PMP
,
pubmed-author:ReillyR MRM
,
pubmed-author:Rockow-MagnoneS KSK
,
pubmed-author:RueterAA
,
pubmed-author:SeverinJ MJM
,
pubmed-author:SimmerR LRL
,
pubmed-author:TahirS KSK
pubmed:issnType
Print
pubmed:volume
21
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
23-8
pubmed:dateRevised
2011-11-2
pubmed:meshHeading
pubmed-meshheading:11299740-Alkaloids
,
pubmed-meshheading:11299740-Antineoplastic Agents
,
pubmed-meshheading:11299740-Apoptosis
,
pubmed-meshheading:11299740-Cell Line, Transformed
,
pubmed-meshheading:11299740-DNA Damage
,
pubmed-meshheading:11299740-Doxorubicin
,
pubmed-meshheading:11299740-Enzyme Inhibitors
,
pubmed-meshheading:11299740-G2 Phase
,
pubmed-meshheading:11299740-Humans
,
pubmed-meshheading:11299740-Neoplasms
,
pubmed-meshheading:11299740-Protein Kinases
,
pubmed-meshheading:11299740-Staurosporine
,
pubmed-meshheading:11299740-Tumor Cells, Cultured
,
pubmed-meshheading:11299740-Tumor Suppressor Protein p53
pubmed:articleTitle
Abrogation of G2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents.
pubmed:affiliation
Department 47S AP9A, Cancer Research, Pharmaceutical Products Division, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA.
pubmed:publicationType
Journal Article